Valuation: Revance Therapeutics, Inc.

Market Cap 319M 280M 264M 241M 451M 30.57B 454M 3.16B 1.22B 15.62B 1.2B 1.17B 50.19B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 477M 450M 410M 768M 52.08B 774M 5.39B 2.09B 26.61B 2.04B 2B 85.52B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
12.58
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-70.92% 383M
-1.00%+0.41%+41.86%-5.58% 78.69B
+2.08%+29.11%+708.13%+102.59% 79.4B
-1.21%+0.77%-10.63%-30.06% 59.52B
-1.80%-2.29%-13.07%+28.02% 46.53B
+1.18%+3.03%+9.11%+169.01% 46.58B
+0.55%+5.61%+67.76%-10.75% 33.63B
-0.44%-1.13%+51.71%+110.88% 25.11B
-0.10%+3.21%+4.89%+155.64% 22.13B
+0.05%-2.42%+57.59%+97.38% 15.31B
Average -0.29%+3.64%+91.74%+54.62% 40.73B
Weighted average by Cap. -0.51%+6.44%+155.35%+55.06%

Financials

2022 2023
Net sales 133M 116M 110M 100M 187M 12.71B 189M 1.31B 509M 6.49B 498M 487M 20.86B 234M 205M 194M 177M 331M 22.43B 333M 2.32B 899M 11.46B 879M 860M 36.83B
Net income -356M -313M -295M -269M -504M -34.16B -508M -3.53B -1.37B -17.45B -1.34B -1.31B -56.09B -324M -284M -269M -245M -458M -31.05B -461M -3.21B -1.24B -15.86B -1.22B -1.19B -50.99B
Net Debt 77.76M 68.24M 64.45M 58.73M 110M 7.45B 111M 771M 299M 3.81B 292M 286M 12.24B 225M 197M 186M 170M 317M 21.52B 320M 2.23B 862M 10.99B 843M 825M 35.33B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock